HRF20/CD59 complement regulatory protein expression is phenotype-dependent and inducible by the hypomethylating agent 5-azacytidine on Burkitt's lymphoma cell lines

Mikio Kuraya, J. Mináróvits, Hidechika Okada, Eva Klein

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We studied the expression of the 20-kDa homologous restriction factor (CD59/HRF20), a complement regulatory protein, on two subsets of blood derived B cells and on Burkitt's lymphoma lines. Both low-density (activated) and high-density (resting) B cell populations expressed high levels of CD59. CD59 was detectable, however, only on a minority of cells or not at all on three Epstein-Barr virus (EBV)-negative BL lines (BL41, BL28 and DG75) and on clones of an EBV-positive BL line (Mutu) that phenotypically resembled resting B lymphocytes. On the other hand, CD59 was detected at high or medium levels on Mutu cells which had a lymphoblastoid cell-like phenotype. Expression of CD59 was upregulated by 5-azacytidine, a drug inhibiting cytosine methylation, on CD59-negative cell lines. Induction was accompanied by a partial hypomethylation in the 5′ region of CD59 coding sequences.

Original languageEnglish
Pages (from-to)35-39
Number of pages5
JournalImmunology Letters
Volume37
Issue number1
DOIs
Publication statusPublished - 1993

Fingerprint

CD59 Antigens
Azacitidine
Burkitt Lymphoma
Complement System Proteins
B-Lymphocytes
Human Herpesvirus 4
Phenotype
Cell Line
Cytosine
Methylation
Clone Cells
Pharmaceutical Preparations
Population

Keywords

  • B lymphocyte
  • Burkitt's lymphoma line
  • CD59/HRF20
  • DNA methylation
  • Epstein-Barr virus

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

HRF20/CD59 complement regulatory protein expression is phenotype-dependent and inducible by the hypomethylating agent 5-azacytidine on Burkitt's lymphoma cell lines. / Kuraya, Mikio; Mináróvits, J.; Okada, Hidechika; Klein, Eva.

In: Immunology Letters, Vol. 37, No. 1, 1993, p. 35-39.

Research output: Contribution to journalArticle

@article{28637c11f2654effae15797338bb0ae4,
title = "HRF20/CD59 complement regulatory protein expression is phenotype-dependent and inducible by the hypomethylating agent 5-azacytidine on Burkitt's lymphoma cell lines",
abstract = "We studied the expression of the 20-kDa homologous restriction factor (CD59/HRF20), a complement regulatory protein, on two subsets of blood derived B cells and on Burkitt's lymphoma lines. Both low-density (activated) and high-density (resting) B cell populations expressed high levels of CD59. CD59 was detectable, however, only on a minority of cells or not at all on three Epstein-Barr virus (EBV)-negative BL lines (BL41, BL28 and DG75) and on clones of an EBV-positive BL line (Mutu) that phenotypically resembled resting B lymphocytes. On the other hand, CD59 was detected at high or medium levels on Mutu cells which had a lymphoblastoid cell-like phenotype. Expression of CD59 was upregulated by 5-azacytidine, a drug inhibiting cytosine methylation, on CD59-negative cell lines. Induction was accompanied by a partial hypomethylation in the 5′ region of CD59 coding sequences.",
keywords = "B lymphocyte, Burkitt's lymphoma line, CD59/HRF20, DNA methylation, Epstein-Barr virus",
author = "Mikio Kuraya and J. Min{\'a}r{\'o}vits and Hidechika Okada and Eva Klein",
year = "1993",
doi = "10.1016/0165-2478(93)90129-P",
language = "English",
volume = "37",
pages = "35--39",
journal = "Immunology Letters",
issn = "0165-2478",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - HRF20/CD59 complement regulatory protein expression is phenotype-dependent and inducible by the hypomethylating agent 5-azacytidine on Burkitt's lymphoma cell lines

AU - Kuraya, Mikio

AU - Mináróvits, J.

AU - Okada, Hidechika

AU - Klein, Eva

PY - 1993

Y1 - 1993

N2 - We studied the expression of the 20-kDa homologous restriction factor (CD59/HRF20), a complement regulatory protein, on two subsets of blood derived B cells and on Burkitt's lymphoma lines. Both low-density (activated) and high-density (resting) B cell populations expressed high levels of CD59. CD59 was detectable, however, only on a minority of cells or not at all on three Epstein-Barr virus (EBV)-negative BL lines (BL41, BL28 and DG75) and on clones of an EBV-positive BL line (Mutu) that phenotypically resembled resting B lymphocytes. On the other hand, CD59 was detected at high or medium levels on Mutu cells which had a lymphoblastoid cell-like phenotype. Expression of CD59 was upregulated by 5-azacytidine, a drug inhibiting cytosine methylation, on CD59-negative cell lines. Induction was accompanied by a partial hypomethylation in the 5′ region of CD59 coding sequences.

AB - We studied the expression of the 20-kDa homologous restriction factor (CD59/HRF20), a complement regulatory protein, on two subsets of blood derived B cells and on Burkitt's lymphoma lines. Both low-density (activated) and high-density (resting) B cell populations expressed high levels of CD59. CD59 was detectable, however, only on a minority of cells or not at all on three Epstein-Barr virus (EBV)-negative BL lines (BL41, BL28 and DG75) and on clones of an EBV-positive BL line (Mutu) that phenotypically resembled resting B lymphocytes. On the other hand, CD59 was detected at high or medium levels on Mutu cells which had a lymphoblastoid cell-like phenotype. Expression of CD59 was upregulated by 5-azacytidine, a drug inhibiting cytosine methylation, on CD59-negative cell lines. Induction was accompanied by a partial hypomethylation in the 5′ region of CD59 coding sequences.

KW - B lymphocyte

KW - Burkitt's lymphoma line

KW - CD59/HRF20

KW - DNA methylation

KW - Epstein-Barr virus

UR - http://www.scopus.com/inward/record.url?scp=0027218270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027218270&partnerID=8YFLogxK

U2 - 10.1016/0165-2478(93)90129-P

DO - 10.1016/0165-2478(93)90129-P

M3 - Article

C2 - 7693582

AN - SCOPUS:0027218270

VL - 37

SP - 35

EP - 39

JO - Immunology Letters

JF - Immunology Letters

SN - 0165-2478

IS - 1

ER -